Search

Your search keyword '"Mantry, Parvez"' showing total 345 results

Search Constraints

Start Over You searched for: Author "Mantry, Parvez" Remove constraint Author: "Mantry, Parvez"
345 results on '"Mantry, Parvez"'

Search Results

2. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

3. WED-211 Combination of Liverfast (LF) and Liver Stiffness Measurement (LSM) using fibroscan uutperforms FIB-4 and LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)

4. LBO-005 Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial

5. WED-294 The use of the FibroScan-AST score and AST to pre-identify metabolic dysfunction-associated steatohepatitis patients with active fibrogenesis in a Phase 1b open-label clinical trial

6. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

7. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

8. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

9. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

10. Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.

11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

12. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma

13. First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.

14. FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.

15. Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.

21. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

23. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

24. Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply.

28. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial

29. Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

39. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

42. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

44. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

47. Featured Cover.

50. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study

Catalog

Books, media, physical & digital resources